Multi-Faceted Role of Luteolin in Cancer Metastasis: EMT, Angiogenesis, ECM Degradation and Apoptosis
暂无分享,去创建一个
[1] J. Kirkland. Tumor dormancy and disease recurrence , 2023, Cancer and Metastasis Reviews.
[2] B. Gălățeanu,et al. Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions , 2023, International journal of molecular sciences.
[3] A. Yezzi,et al. Anti-Arthritic and Anti-Cancer Activities of Polyphenols: A Review of the Most Recent In Vitro Assays , 2023, Life.
[4] M. Rizzo,et al. A Nutraceutical Containing Chlorogenic Acid and Luteolin Improves Cardiometabolic Parameters in Subjects with Pre-obesity: A 6-Month Randomized, Double-Blind, Placebo-Controlled Study , 2023, Nutrients.
[5] J. Sharifi‐Rad,et al. Luteolin: a flavonoid with a multifaceted anticancer potential , 2022, Cancer Cell International.
[6] R. Maestri,et al. Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABAB-ergic activity and cortical plasticity in long COVID-19 syndrome , 2022, Clinical Neurophysiology.
[7] M. Kumar,et al. Luteolin, a Potent Anticancer Compound: From Chemistry to Cellular Interactions and Synergetic Perspectives , 2022, Cancers.
[8] Shan Wu,et al. Luteolin Suppresses Three Angiogenesis Modes and Cell Interaction in Uveal Melanoma in Vitro , 2022, Current eye research.
[9] M. Brenner,et al. Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study , 2022, Cells.
[10] M. Brenner,et al. Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial , 2022, Current neuropharmacology.
[11] M. Brenner,et al. Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial , 2022, Current Neuropharmacology.
[12] A. Jemal,et al. Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.
[13] Xiaoping Cai,et al. Luteolin inhibits viability, migration, angiogenesis and invasion of non-small cell lung cancer vascular endothelial cells via miR-133a-3p/purine rich element binding protein B-mediated MAPK and PI3K/Akt signaling pathways. , 2022, Tissue & cell.
[14] S. Niland,et al. Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression , 2021, International journal of molecular sciences.
[15] H. Liao,et al. Luteolin inhibits the proliferation, adhesion, migration and invasion of choroidal melanoma cells in vitro. , 2021, Experimental eye research.
[16] M. Aschner,et al. Luteolin and cancer metastasis suppression: focus on the role of epithelial to mesenchymal transition , 2021, Medical Oncology.
[17] K. Tomczak,et al. Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing , 2021, Proceedings of the National Academy of Sciences.
[18] G. Jayandharan,et al. Vector engineering, strategies and targets in cancer gene therapy , 2021, Cancer Gene Therapy.
[19] N. Tran,et al. miRNA interplay: mechanisms and consequences in cancer , 2021, Disease models & mechanisms.
[20] P. Bonadonna,et al. Hypersensitivity reactions to chemotherapy: an EAACI Position Paper , 2021, Allergy.
[21] A. Girotti,et al. Advanced nanomedicine and cancer: challenges and opportunities in clinical translation. , 2021, International journal of pharmaceutics.
[22] Shenglan Yang,et al. EMT‐associated microRNAs and their roles in cancer stemness and drug resistance , 2021, Cancer communications.
[23] V. Intasanta,et al. Polymerized Luteolin Nanoparticles: Synthesis, Structure Elucidation, and Anti-Inflammatory Activity , 2021, ACS omega.
[24] K. Bajbouj,et al. Luteolin inhibits proliferation, triggers apoptosis and modulates Akt/mTOR and MAP kinase pathways in HeLa cells , 2021, Oncology letters.
[25] Zhen Liu,et al. The flavonoid luteolin suppresses infantile hemangioma by targeting FZD6 in the Wnt pathway , 2021, Investigational New Drugs.
[26] Dar-Ren Chen,et al. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway. , 2020, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[27] I. Mackraj,et al. The effect of hesperidin and luteolin isolated from Eriocephalus africanus on apoptosis, cell cycle and miRNA expression in MCF-7 , 2020, Journal of biomolecular structure & dynamics.
[28] Yunbo Wei,et al. Luteolin, an aryl hydrocarbon receptor ligand, suppresses tumor metastasis in vitro and in vivo. , 2020, Oncology reports.
[29] Guo‐Yuan Zhu,et al. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[30] Anubhab Mukherjee,et al. Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer , 2020, International journal of molecular sciences.
[31] S. Sridhar,et al. Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] T. Ko,et al. Dietary Flavonoids Luteolin and Quercetin Inhibit Migration and Invasion of Squamous Carcinoma through Reduction of Src/Stat3/S100A7 Signaling , 2019, Antioxidants.
[33] Xin‐an Zeng,et al. Novel extraction techniques and pharmaceutical activities of luteolin and its derivatives. , 2019, Journal of food biochemistry.
[34] M. Medina,et al. The Mediterranean Diet, a Rich Source of Angiopreventive Compounds in Cancer , 2019, Nutrients.
[35] B. Keikhaei,et al. A review of molecular mechanisms involved in anticancer and antiangiogenic effects of natural polyphenolic compounds , 2019, Phytotherapy research : PTR.
[36] G. Gao,et al. Luteolin exhibits anti-breast cancer property through up-regulating miR-203 , 2019, Artificial cells, nanomedicine, and biotechnology.
[37] Ajeet Singh,et al. Synthesis of luteolin loaded zein nanoparticles for targeted cancer therapy improving bioavailability and efficacy , 2019, Journal of Drug Delivery Science and Technology.
[38] F. Barber. Adverse Events of Oncologic Immunotherapy and Their Management , 2019, Asia-Pacific journal of oncology nursing.
[39] Jun Ren,et al. A Review on the Antioxidative and Prooxidative Properties of Luteolin , 2019, Reactive Oxygen Species.
[40] Yuanyuan Yao,et al. Luteolin suppresses colorectal cancer cell metastasis via regulation of the miR-384/pleiotrophin axis , 2019, Oncology reports.
[41] M. Shariati,et al. Luteolin, a flavonoid, as an anticancer agent: A review. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[42] H. Lan,et al. Luteolin inhibits cell cycle progression and induces apoptosis of breast cancer cells through downregulation of human telomerase reverse transcriptase , 2019, Oncology letters.
[43] Qi Wang,et al. HIF‐1α/VEGF signaling‐mediated epithelial–mesenchymal transition and angiogenesis is critically involved in anti‐metastasis effect of luteolin in melanoma cells , 2019, Phytotherapy research : PTR.
[44] A. Sinha,et al. Enhanced Induction of Apoptosis in HaCaT Cells by Luteolin Encapsulated in PEGylated Liposomes—Role of Caspase-3/Caspase-14 , 2018, Applied Biochemistry and Biotechnology.
[45] K. Nakagawa,et al. Absorption and Metabolism of Luteolin in Rats and Humans in Relation to in Vitro Anti-inflammatory Effects. , 2018, Journal of agricultural and food chemistry.
[46] A. Cervantes,et al. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] Tao Zhang,et al. Luteolin exerts an anticancer effect on gastric cancer cells through multiple signaling pathways and regulating miRNAs , 2018, Journal of Cancer.
[48] Rebecca J. Gryka,et al. Luteolin Decreases Epidermal Growth Factor Receptor‐Mediated Cell Proliferation and Induces Apoptosis in Glioblastoma Cell Lines , 2018, Basic & clinical pharmacology & toxicology.
[49] Minmin Wu,et al. Luteolin inhibits angiogenesis of the M2‑like TAMs via the downregulation of hypoxia inducible factor‑1α and the STAT3 signalling pathway under hypoxia. , 2018, Molecular medicine reports.
[50] Yun-Ru Chen,et al. Stimulation of Fas/FasL‐mediated apoptosis by luteolin through enhancement of histone H3 acetylation and c‐Jun activation in HL‐60 leukemia cells , 2018, Molecular Carcinogenesis.
[51] Matthew T. Cook. Mechanism of metastasis suppression by luteolin in breast cancer , 2018, Breast cancer.
[52] Cheng-Ying Chu,et al. Flavonoids Luteolin and Quercetin Inhibit RPS19 and contributes to metastasis of cancer cells through c-Myc reduction , 2018, Journal of food and drug analysis.
[53] Mian-hua Wu,et al. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p , 2018, International journal of molecular sciences.
[54] D. Pinto,et al. Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application , 2018, International journal of molecular sciences.
[55] Kurexi Yunusi,et al. Liposome encapsulated luteolin showed enhanced antitumor efficacy to colorectal carcinoma , 2017, Molecular medicine reports.
[56] K. Kang,et al. Luteolin induces apoptotic cell death via antioxidant activity in human colon cancer cells. , 2017, International journal of oncology.
[57] Bingya Liu,et al. Luteolin suppresses angiogenesis and vasculogenic mimicry formation through inhibiting Notch1-VEGF signaling in gastric cancer. , 2017, Biochemical and biophysical research communications.
[58] Mohini Singh,et al. EMT: Mechanisms and therapeutic implications , 2017, Pharmacology & therapeutics.
[59] Chunying Gao,et al. Pharmacokinetics, tissue distribution and excretion of luteolin and its major metabolites in rats: Metabolites predominate in blood, tissues and are mainly excreted via bile , 2017 .
[60] Han-dong Wang,et al. Luteolin reduces migration of human glioblastoma cell lines via inhibition of the p-IGF-1R/PI3K/AKT/mTOR signaling pathway , 2017, Oncology letters.
[61] H. Aisa,et al. Luteolin induces apoptosis in vitro through suppressing the MAPK and PI3K signaling pathways in gastric cancer , 2017, Oncology letters.
[62] P. Wee,et al. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways , 2017, Cancers.
[63] Chen Li,et al. Luteolin suppresses gastric cancer progression by reversing epithelial-mesenchymal transition via suppression of the Notch signaling pathway , 2017, Journal of Translational Medicine.
[64] J. Wan,et al. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression. , 2017, Oncology reports.
[65] C. Besch-Williford,et al. Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells. , 2016 .
[66] P. Kantoff,et al. Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.
[67] L. Senggunprai,et al. Luteolin induces cholangiocarcinoma cell apoptosis through the mitochondrial‐dependent pathway mediated by reactive oxygen species , 2016, The Journal of pharmacy and pharmacology.
[68] Yongning Sun,et al. Luteolin inhibited proliferation and induced apoptosis of prostate cancer cells through miR-301 , 2016, OncoTargets and therapy.
[69] D. Trisciuoglio,et al. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies , 2016, Aging.
[70] L. Wan,et al. Flavones inhibit breast cancer proliferation through the Akt/FOXO3a signaling pathway , 2015, BMC Cancer.
[71] Y. Shu,et al. Luteolin Induces Apoptosis by Up-regulating miR-34a in Human Gastric Cancer Cells , 2015, Technology in cancer research & treatment.
[72] A. Azmi,et al. Broad targeting of angiogenesis for cancer prevention and therapy , 2015, Seminars in cancer biology.
[73] A. Azmi,et al. Tissue invasion and metastasis: Molecular, biological and clinical perspectives. , 2015, Seminars in cancer biology.
[74] He-da Zhang,et al. Luteolin Inhibits Breast Cancer Development and Progression In Vitro and In Vivo by Suppressing Notch Signaling and Regulating MiRNAs , 2015, Cellular Physiology and Biochemistry.
[75] Mengtao Zhou,et al. Luteolin decreases invasiveness, deactivates STAT3 signaling, and reverses interleukin-6 induced epithelial–mesenchymal transition and matrix metalloproteinase secretion of pancreatic cancer cells , 2015, OncoTargets and therapy.
[76] C. Besch-Williford,et al. Luteolin inhibits progestin-dependent angiogenesis, stem cell-like characteristics, and growth of human breast cancer xenografts , 2015, SpringerPlus.
[77] Jie Cheng,et al. The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer , 2015, Molecular oncology.
[78] Zhongqi Li,et al. Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer , 2015, Journal of Translational Medicine.
[79] N. Peppas,et al. Intelligent Nanoparticles for Advanced Drug Delivery in Cancer Treatment. , 2015, Current opinion in chemical engineering.
[80] R. Derynck,et al. Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition. , 2014, Current opinion in cell biology.
[81] D. Medici,et al. Signaling mechanisms of the epithelial-mesenchymal transition , 2014, Science Signaling.
[82] Samy Lamouille,et al. Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.
[83] Tsung-Ying Yang,et al. Luteolin attenuates TGF-β1-induced epithelial-mesenchymal transition of lung cancer cells by interfering in the PI3K/Akt-NF-κB-Snail pathway. , 2013, Life sciences.
[84] S. Jung,et al. Raf and PI3K are the Molecular Targets for the Anti‐metastatic Effect of Luteolin , 2013, Phytotherapy research : PTR.
[85] E. Zintzaras,et al. An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. , 2013, Clinical therapeutics.
[86] Xianglin Shi,et al. Luteolin Inhibits Human Prostate Tumor Growth by Suppressing Vascular Endothelial Growth Factor Receptor 2-Mediated Angiogenesis , 2012, PloS one.
[87] A. Harris,et al. How cancer metabolism is tuned for proliferation and vulnerable to disruption , 2012, Nature.
[88] Xueting Cai,et al. The molecular mechanism of luteolin-induced apoptosis is potentially related to inhibition of angiogenesis in human pancreatic carcinoma cells. , 2012, Oncology reports.
[89] J. Matés,et al. Oxidative stress in apoptosis and cancer: an update , 2012, Archives of Toxicology.
[90] Yin Lu,et al. Luteolin reduces the invasive potential of malignant melanoma cells by targeting β3 integrin and the epithelial-mesenchymal transition , 2012, Acta Pharmacologica Sinica.
[91] Yin Lu,et al. Inhibition of hypoxia-induced epithelial mesenchymal transition by luteolin in non-small cell lung cancer cells. , 2012, Molecular medicine reports.
[92] Sven Diederichs,et al. The hallmarks of cancer , 2012, RNA biology.
[93] J. Wolchok,et al. Antibody therapy of cancer , 2012, Nature Reviews Cancer.
[94] H. Steller,et al. Programmed Cell Death in Animal Development and Disease , 2011, Cell.
[95] P. Carmeliet,et al. Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.
[96] Xiaoyuan Chen,et al. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. , 2010, Current drug targets.
[97] Anindya Dutta,et al. MicroRNAs in cancer. , 2009, Annual review of pathology.
[98] K. Watabe,et al. Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. , 2008, Biochimica et biophysica acta.
[99] S. Zeng,et al. Intestinal absorption of luteolin from peanut hull extract is more efficient than that from individual pure luteolin. , 2008, Journal of agricultural and food chemistry.
[100] R. Weinberg,et al. Adaptation versus selection: the origins of metastatic behavior. , 2007, Cancer research.
[101] S. Elmore. Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.
[102] S. Belinsky,et al. A Critical Role of Luteolin-Induced Reactive Oxygen Species in Blockage of Tumor Necrosis Factor-Activated Nuclear Factor-κB Pathway and Sensitization of Apoptosis in Lung Cancer Cells , 2007, Molecular Pharmacology.
[103] J. Quigley,et al. Matrix metalloproteinases and tumor metastasis , 2006, Cancer and Metastasis Reviews.
[104] M. Nair,et al. From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer , 2006, Expert opinion on therapeutic targets.
[105] M. Oshimura,et al. PI3K-Akt pathway: Its functions and alterations in human cancer , 2004, Apoptosis.
[106] L. Morbidelli,et al. Luteolin Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis; Inhibition of Endothelial Cell Survival and Proliferation by Targeting Phosphatidylinositol 3′-Kinase Activity , 2004, Cancer Research.
[107] Enrique Casado,et al. PI3K/Akt signalling pathway and cancer. , 2004, Cancer treatment reviews.
[108] M. Nair,et al. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. , 2002, Anticancer research.
[109] S. De Flora,et al. ‘Angioprevention’: angiogenesis is a common and key target for cancer chemopreventive agents , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[110] E. De Clercq,et al. Angiogenesis: regulators and clinical applications. , 2001, Biochemical pharmacology.
[111] P. Basset,et al. Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. , 1997, Matrix biology : journal of the International Society for Matrix Biology.
[112] H. Liao,et al. Effect of luteolin on apoptosis and vascular endothelial growth factor in human choroidal melanoma cells. , 2021, International journal of ophthalmology.
[113] L. Fu,et al. Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors. , 2014, American journal of cancer research.
[114] A. Pandurangan,et al. Luteolin induces growth arrest in colon cancer cells through involvement of Wnt/β-catenin/GSK-3β signaling. , 2013, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.
[115] A. Azzariti,et al. EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. , 2011, Frontiers in bioscience.
[116] Paul C. Wang,et al. Circumventing tumor resistance to chemotherapy by nanotechnology. , 2010, Methods in molecular biology.
[117] M. López-Lázaro. Distribution and biological activities of the flavonoid luteolin. , 2009, Mini reviews in medicinal chemistry.
[118] G. Tuszynski,et al. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis , 2009, Pathology Oncology Research.
[119] A. Tyner,et al. Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. , 2007, American journal of physiology. Gastrointestinal and liver physiology.
[120] V. Kim,et al. Small RNAs : Classification , Biogenesis , and Function , 2005 .
[121] J. Ross,et al. Dietary flavonoids: bioavailability, metabolic effects, and safety. , 2002, Annual review of nutrition.